الإحصائيات الأساسية
| LEI | 5493002Z0KHRW71RNC19 |
| CIK | 1513818 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aravive, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Aravive, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03890D108 (CUSIP Number) December |
|
| February 14, 2024 |
ARAV / Aravive, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2024 |
ARAV / Aravive, Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A 1 d688791dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 3) Aravive, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03890D108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-3631 Aravive, Inc. (Exact name of registrant as specified in its charter |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36361 ARAVIVE, INC.; Nasdaq Global Select Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Address: Ri |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 17, 2024 |
CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE Exhibit 10.2 CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE This Confidential Separation Agreement and Release (the “Agreement”) is entered into between Aravive, Inc. and its related entities (the “Company”) and Gail McIntyre (the “Employee”), in connection with the end of the employment relationship between Employee and the Company, to assist Employee in transitioning to new employment, and to rel |
|
| January 17, 2024 |
CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE Exhibit 10.3 CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE This Confidential Separation Agreement and Release (the “Agreement”) is entered into between Aravive, Inc. and its related entities (the “Company”) and Rudy Howard (the “Employee”), in connection with the end of the employment relationship between Employee and the Company, to assist Employee in transitioning to new employment, and to relea |
|
| January 17, 2024 |
Aravive, Inc. to Delist from The Nasdaq Stock Market Exhibit 99.1 Aravive, Inc. to Delist from The Nasdaq Stock Market January 17, 2024 HOUSTON, January 17, 2024 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market (“Nasdaq”) and, based upon ownership of its shares by fewer than 300 holders of record, deregi |
|
| January 17, 2024 |
Exhibit 10.1 GENERAL ASSIGNMENT This General Assignment is made as of January 17, 2024, by Aravive, Inc., a Delaware corporation, with offices at River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, TX 77098, hereinafter referred to as “Assignor”, to Aravive (assignment for the benefit of creditors), LLC, a California limited liability company, hereinafter referred to, along with any successors |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3636 |
|
| November 3, 2023 |
-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission F |
|
| November 3, 2023 |
ARAVIVE, INC. AMENDMENT TO AMENDED AND RESTATED BYLAWS Exhibit 3.1 ARAVIVE, INC. AMENDMENT TO AMENDED AND RESTATED BYLAWS This Amendment to the Amended and Restated Bylaws (the “Bylaws”) of Aravive, Inc., as adopted by the Board of Directors pursuant to Article XIII, Section 43, of said Bylaws, is effective as of the 2nd day of November, 2023. Article III, Section 8, of the Bylaws, entitled “Quorum”, be, and hereby is, deleted in its entirety and repl |
|
| October 3, 2023 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| September 19, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36361 Ara |
|
| August 14, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12B-25 NOTIFICATION OF LATE FILING SEC file number: 001-36361 CUSIP: 03890D108 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on |
|
| August 2, 2023 |
Exhibit 99.1 Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer ● Trial did not meet primary endpoint of progression-free survival ● Cash at the end of Q2 of approximately $18M (unaudited) is expected to be sufficient to fund operations into early Q4 2023 HOUSTON, August 2, 2023 (GLOBE NEWSWIRE) – Aravive, Inc. (Nasdaq: ARAV, “the |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 28, 2023 |
$250,000,000 Common Stock Preferred Stock Debt Securities Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-272775 PROSPECTUS $250,000,000 Common Stock Preferred Stock Debt Securities Warrants Units We may, from time to time, offer and sell up to $250,000,000 of any combination of our common stock, preferred stock, debt securities or warrants described in this prospectus, either individually or in combination with other securities, |
|
| June 26, 2023 |
River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 (936) 355-1910 River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 (936) 355-1910 June 26, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 20, 2023 |
As filed with the Securities and Exchange Commission on June 20, 2023 Table of Contents As filed with the Securities and Exchange Commission on June 20, 2023 Registration Statement No. |
|
| June 20, 2023 |
Exhibit 4.4 ARAVIVE, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2.03 Den |
|
| June 20, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Aravive, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be paid Eq |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 5, 2023 |
Company Presentation of Aravive, Inc. dated June 2023 Exhibit 99.1 |
|
| May 25, 2023 |
Exhibit 99.1 Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023 HOUSTON, TX, May 25, 2023 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of upd |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 25, 2023 |
Exhibit 99.2 Phase 2 Study of Batiraxcept (AVB-S6-500, an AXL inhibitor) as Monotherapy, in combination with Cabozantinib (Cabo), and in combination with Cabo and Nivolumab (Nivo) in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC). Katy Beckermann, Matthew T Campbell, Naomi B. Haas, Moshe Chaim Ornstein, Xin Gao, Shifeng S. Mao, Hans J. Hammers, Saby George, Ariel Ann Nelson, Theodo |
|
| May 16, 2023 |
Investor Presentation of Aravive, Inc. dated May 2023 Exhibit 99.2 |
|
| May 16, 2023 |
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma Exhibit 99.1 Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma ● Trial initiation anticipated in 2H 2023 with topline data anticipated in 2H 2025 ● Updated Phase 1b/2 ccRCC data to be presented at ASCO 2023 HOUSTON, TX, May 16, 2023 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted ther |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36361 Ar |
|
| May 10, 2023 |
May 10, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 10, 2023 |
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates Exhibit 99.1 Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates ● On Track for PROC Pivotal Phase 3 Trial Readout Mid-2023 ● Promising ccRCC Phase 1b/2 Results to Date; Update to be Presented at ASCO 2023 ● Strengthened Management Team with Appointment of Carolina Petrini as Chief Commercial Officer ● Company hosting Key Opinion Leader (KOL) webinar featuring batir |
|
| April 19, 2023 |
As filed with the Securities and Exchange Commission on April 19, 2023 As filed with the Securities and Exchange Commission on April 19, 2023 Registration No. |
|
| April 19, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aravive, Inc. (Exact Name of Registrant as Specified in its Charter) Table1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 pe |
|
| April 11, 2023 |
Exhibit 10.2 Aravive, Inc. Stock Option Grant Notice Aravive, Inc. (the “Company”) has granted to you (the “Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). The Option is granted upon the terms, and subject to the conditions, set forth in this Grant Notice and the Option Agreement as attached hereto (the “Terms and Conditions”), each her |
|
| April 11, 2023 |
Aravive Appoints Carolina Petrini as Chief Commercial Officer Exhibit 99.1 Aravive Appoints Carolina Petrini as Chief Commercial Officer HOUSTON, TX, April 11, 2023 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Carolina Petrini as the Company’s new Chief Commercial Officer effective April 10, 2023. Ms. Petr |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 11, 2023 |
Offer Letter, dated April 10, 2023, by and between Aravive, Inc. and Maria Carolina Petrini Exhibit 10.1 Aravive, Inc. River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, TX 77098 March 18, 2023 Carolina Petrini Via Email Delivery: ##### Dear Ms. Petrini, Aravive, Inc. (the "Company") is pleased to offer you employment on the following terms: 1) Position a) Your initial title will be Chief Commercial Officer. This is a full-time position, and you will report to Gail McIntyre, Chief Ex |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 15, 2023 |
Exhibit 99.1 Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash Position HOUSTON, TX, March 15, 2023 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat met |
|
| March 15, 2023 |
Description of Capital Securities. Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Aravive, Inc. (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which is our common stock, par value $0.0001 per share (the “common stock”). General The following is a descri |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-363 |
|
| March 15, 2023 |
Exhibit 21.1 SUBSIDIARIES Aravive Biologics, Inc. (Delaware) |
|
| February 28, 2023 |
Exhibit 99.1 Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer ● Dose escalation portion of ongoing Phase 1b/2 pancreatic adenocarcinoma trial initiated, with preliminary results expected in 2H 2023 HOUSTON, TX, February 28, 2023 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developin |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 14, 2023 |
EX-99.1 2 tm234999d7ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Aravive, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2023 BAKER BROS. ADVISORS LP By: |
|
| February 14, 2023 |
ARAV / Aravive Inc / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SC 13G 1 tm234999d7sc13g.htm SC 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Aravive, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03890D108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 13, 2023 |
Exhibit 99.1 Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium HOUSTON, TX, February 13, 2023 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat |
|
| February 13, 2023 |
ARAV / Aravive Inc / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A 1 d395595dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Aravive, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03890D108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 13, 2023 |
Exhibit 99.2 |
|
| February 6, 2023 |
Exhibit 10.2 River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 Rudy C. Howard Via Email Delivery: February 1, 2023 Dear Rudy: Aravive, Inc. (the “Company”) is pleased to enter into this amendment (“Amendment”) to your Offer Letter, dated June 2, 2022 (the “Offer Letter”), and hereby agrees to amend the Offer Letter as follows: 1. The first and second sentences of Section 3 are her |
|
| February 6, 2023 |
Exhibit 10.3 River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 Robert B. Geller, M.D. Via Email Delivery: February 1, 2023 Dear Robert: Aravive, Inc. (the “Company”) is pleased to enter into this amendment (“Amendment”) to your Offer Letter, dated June 13, 2022 (the “Offer Letter”), and hereby agrees to amend the Offer Letter as follows: 1. The first and second sentences of Sectio |
|
| February 6, 2023 |
Exhibit 10.4 River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 Leonard Scott Dove, Ph.D. Via Email Delivery: [****] February 1, 2023 Dear Scott: Aravive, Inc. (the “Company”) is pleased to enter into this amendment (“Amendment”) to your Offer Letter, dated February 20, 2022 (the “Offer Letter”), and hereby agrees to amend the Offer Letter as follows: 1. The first and second senten |
|
| February 6, 2023 |
Exhibit 10.1 River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 Gail McIntyre (via email: [****]) February 1, 2023 Dear Gail: Aravive, Inc. (the “Company”) is pleased to enter into this amendment (“Amendment”) to your Offer Letter, dated March 26, 2020, as amended on April 8, 2021 and January 25, 2021 (the “Offer Letter”), and hereby agrees to amend the Offer Letter as follows: 1. |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 18, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARAVIVE, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Aravive, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HER |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 4, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 4, 2023 |
Exhibit 99.1 Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer ? Topline data expected mid-2023 ? Potential Biologics License Application (BLA) submission end of 2023 HOUSTON, TX, January 4, 2023 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, the ?Company?), a late clinical-stage oncology company developing targeted |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 28, 2022 |
ARAV / Aravive Inc / Zhang Eric - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03890D108 (CUSIP Number) Eric Zhang c/o Elite Vantage Global Limited Suite 1807, 18F China Resources Building 26 Harbor Road Wan Chai, Hong Kong With |
|
| December 27, 2022 |
ARAV / Aravive Inc / Giaccia Amato - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03890D108 (CUSIP Number) Amato Giaccia c/o Aravive, Inc. River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 With a copy to: Leslie Mar |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 29, 2022 |
Investor Presentation of Aravive, Inc. dated November 2022 Exhibit 99.2 |
|
| November 29, 2022 |
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC Exhibit 99.1 Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC FDA decision based on new Phase 1b data: Objective Response Rate (ORR) of 57% and median Progression-Free Survival (PFS) of 11.4 months in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endotheli |
|
| November 29, 2022 |
90,357,622 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268471 PROSPECTUS 90,357,622 Shares of Common Stock This prospectus relates to the resale from time to time of up to 90,357,622 shares of common stock, par value $0.0001 per share (the ?Common Stock?), of Aravive, Inc. by the selling stockholders identified in this prospectus (the ?Selling Stockholders?), including their pledg |
|
| November 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 23, 2022 |
November 23, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: Aravive, Inc. Registration Statement on Form S-3 File No. 333-268471 Request For Acceleration Ladies and Gentlemen: Aravive, Inc. (the ?Registrant?) hereby requests that the effective date of the Company?s Registration Statement on |
|
| November 18, 2022 |
As filed with the Securities and Exchange Commission on November 18, 2022 Table of Contents As filed with the Securities and Exchange Commission on November 18, 2022 Registration Statement No. |
|
| November 18, 2022 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Aravive, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Newl |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| November 16, 2022 |
Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement HOUSTON, TX, November 16, 2022 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (“Nasdaq”) on November |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 10, 2022 |
Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates Exhibit 99.1 Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates ? Continued Advancement of Clinical Trials in Platinum Resistant Ovarian Cancer (PROC), Clear Cell Renal Cell Carcinoma and Pancreatic Adenocarcinoma ? Secured Funding to Take the Company Beyond the PROC Readout in Mid-2023 ? Advanced Development of Batiraxcept in China and Received Significant Milesto |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3636 |
|
| November 7, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 7, 2022 with respect to the Common Stock, $0.0001 par value per share, of Aravive, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the pr |
|
| November 7, 2022 |
ARAV / Aravive Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Aravive, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03890D108 (CUSIP Number) October 27 |
|
| November 3, 2022 |
ARAV / Aravive Inc / Eshelman Ventures, LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 03890D108 (CUSIP Number) Fredric N. Eshelman Eshelman Ventures, LLC 319 North Third Street, Suite 301 Wilmington, North Carolina 28401 910-558-6885 wit |
|
| October 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (C |
|
| October 28, 2022 |
Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 24, 2022, by and between Aravive, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms |
|
| October 26, 2022 |
Exhibit 4.3 Execution Copy THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 26, 2022 |
Aravive Announces Approximately $41.5 Million Private Placement Financing Exhibit 99.1 Aravive Announces Approximately $41.5 Million Private Placement Financing Priced At-The-Market with Substantial Participation from both New Life Sciences Specialist Investors as well as Large Existing Investors HOUSTON, October 25, 2022 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV) (?Company?), a late clinical-stage oncology company developing targeted therapeutics to treat metastat |
|
| October 26, 2022 |
Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 24, 2022, by and between Aravive, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms |
|
| October 26, 2022 |
Form of Registration Rights Agreement by and among Aravive, Inc. and the persons party thereto Exhibit 10.4 Execution Copy REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made as of October 24, 2022 by and between Aravive, Inc., a Delaware corporation (the ?Company?), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the ?Investors?). Unless otherwise defined herein, capitalized terms used in this Ag |
|
| October 26, 2022 |
Exhibit 10.5 Execution Copy REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of October 24, 2022 by and among Aravive, Inc., a Delaware corporation (the ?Company?), and the Purchasers named in that certain Securities Purchase Agreement by and among the Company and the Purchasers, dated as of October 24, 2022 (the ?Purchase Agreement?). |
|
| October 26, 2022 |
Form of Side Letter Agreement by and among Aravive, Inc. and the persons party thereto Exhibit 10.2 Execution Copy October 24, 2022 c/o 667, L.P. 860 Washington Street New York, NY 10014 c/o Baker Brothers Life Sciences, L.P. 860 Washington Street New York, NY 10014 Re: Participation, Board, Observer and Publicity Rights Ladies and Gentlemen: Subject to and in consideration of the purchase of (i) shares of common stock, par value $0.0001 per share, (?Common Stock?), of Aravive, Inc. |
|
| October 26, 2022 |
Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i) SUC |
|
| October 26, 2022 |
Form of Side Letter Agreement by and among Aravive, Inc. and the BVF Investor party thereto Exhibit 10.3 Execution Copy October 24, 2022 c/o BVF Partners L.P. 44 Montgomery Street 40th Floor San Francisco CA 94104 Re: Participation and Publicity Rights Ladies and Gentlemen: Subject to and in consideration of the purchase of (i) shares of common stock, par value $0.0001 per share (?Common Stock?), of Aravive, Inc., a Delaware corporation (the ?Company?), (ii) pre-funded warrants to purcha |
|
| October 26, 2022 |
Exhibit 4.2 Execution Copy THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED |
|
| October 11, 2022 |
Aravive Receives Third Development Milestone from 3D Medicines Exhibit 99.1 Aravive Receives Third Development Milestone from 3D Medicines Milestone is Based on 3D Medicines? Initiation of the Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer in China HOUSTON, October 10, 2022 (GLOBE NEWSWIRE) - Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 27, 2022 |
Investor Presentation of Aravive, Inc. dated September 2022 Exhibit 99.1 |
|
| September 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 22, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 26, 2022 |
Investor Presentation of Aravive, Inc. dated August 2022 Exhibit 99.1 |
|
| August 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 26, 2022 |
Investor Presentation of Aravive, Inc. dated August 2022 Exhibit 99.1 |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36361 Ara |
|
| August 11, 2022 |
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates Exhibit 99.1 Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates ? Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b Pancreatic Adenocarcinoma Data. ? Presented Updated Clinical Data at ASCO Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or Metas |
|
| August 11, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 5, 2022 |
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer Exhibit 99.1 Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer - Dr. Geller is a Board-Certified Medical Oncologist with over 30 years of experience in the biopharmaceutical industry and academia Houston, TX, July 5, 2022 - Aravive, Inc. (Nasdaq: ARAV, ?the Company?), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced t |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 5, 2022 |
Offer Letter, dated June 13, 2022, by and between Aravive, Inc. and Dr. Robert B. Geller EX-10.1 2 ex391901.htm EXHIBIT 10.1 Exhibit 10.1 Aravive, Inc. River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, TX 77098 June 13, 2022 Robert B. Geller, M.D. Via Email Delivery: [****] Dear Dr. Geller, Aravive, Inc. (the "Company") is pleased to offer you employment on the following terms: 1) Position a) Your initial title will be Chief Medical Officer. This is a full-time position, and you |
|
| June 3, 2022 |
Separation Agreement and Release, dated June 2, 2022, by and between Aravive, Inc. and Vinay Shah EX-10.3 4 ex382748.htm EXHIBIT 10.3 Exhibit 10.3 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Vinay Shah (“Employee”) and Aravive, Inc. (“Aravive”, or the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed an o |
|
| June 3, 2022 |
Consulting Agreement, dated June 2, 2022, by and between Aravive, Inc. and Vinay Shah Exhibit 10.2 Consulting Agreement This Professional Services Agreement (this ?Agreement?), dated June 2, 2022 (the ?Effective Date?), is by and between Aravive, Inc. (?Company?), and Vinay Shah (?Service Provider?). 1. Services. Service Provider agrees to aid in the transition process following Service Provider?s separation of employment from the Company. Service Provider agrees that the Company w |
|
| June 3, 2022 |
Aravive Appoints Rudy Howard as Chief Financial Officer Exhibit 99.1 Aravive Appoints Rudy Howard as Chief Financial Officer Houston, TX, June 3, 2022 - Aravive, Inc. (Nasdaq: ARAV, the ?Company?), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Rudy Howard as Chief Financial Officer, effective today. Vinay Shah has stepped down as CFO for personal reasons but will |
|
| June 3, 2022 |
Offer Letter, dated June 2, 2022, by and between Aravive, Inc. and Rudy C. Howard Exhibit 10.1 Aravive, Inc. River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, TX 77098 June 2, 2022 Via Email Delivery: rudychoward@***.com Mr. Rudy C. Howard ***** ***** Dear Mr. Howard, Aravive, Inc. (the ?Company?) is pleased to offer you employment on the following terms: 1) Position. a) Your initial title will be Chief Financial Officer. This is a full-time position, and you will report t |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 26, 2022 |
Exhibit 99.1 Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC) - Abstract selected for oral discussion on Genitourinary Cancer on Saturday June 4, 2022 - Development of biomarker offers the potential of a first in class targeted therapy in renal cancer - Company has a registratio |
|
| May 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 26, 2022 |
Exhibit 99.2 A Phase 1b/2 study of Batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) received front-line treatment (NCT04300140) Background: AXL is up-regulated by hypoxia-inducible factor-1 signaling in both VHL-deficient and hypoxic tumor cells and plays a critical role in the metastatic phenotype of ccRCC. B |
|
| May 26, 2022 |
Exhibit 99.3 A Phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140) Background: In clear cell renal cell carcinoma (ccRCC) the constitutive expression of hypoxia induced factor 1-? leads to increased expression of AXL. AXL overexpression has |
|
| May 12, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36361 Ar |
|
| May 12, 2022 |
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates Exhibit 99.1 Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates ? Reported positive updated data and new biomarker data from Phase 1b Study of Batiraxcept in ccRCC ? Presented updated modeling data from batiraxcept clinical trials at the AACR annual meeting ? Dosed first patient in Phase 2 study of batiraxcept in clear cell Renal Cell Carcinoma ? Provided positive |
|
| May 11, 2022 |
Investor Presentation of Aravive, Inc. dated May 2022 Exhibit 99.1 |
|
| May 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 22, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aravive, Inc. (Exact Name of Registrant as Specified in its Charter) Table1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 |
|
| April 22, 2022 |
As filed with the Securities and Exchange Commission on April 22, 2022 As filed with the Securities and Exchange Commission on April 22, 2022 Registration No. |
|
| April 5, 2022 |
ARAV / Aravive Inc / ESHELMAN FREDRIC N - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 03890D108 (CUSIP Number) Fredric N. Eshelman Eshelman Ventures, LLC 319 North Third Street, Suite 301 Wilmington, North Carolina 28401 910-558-6885 with a copy |
|
| April 4, 2022 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 1, 2022 |
Exhibit 99.1 Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules HOUSTON, April 1, 2022 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has closed its previously announced registered direct offering priced at-the-market unde |
|
| March 31, 2022 |
Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 29, 2022, between Aravive, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions s |
|
| March 31, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-363 |
|
| March 31, 2022 |
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it has entered into definitive agreements with a single healthcare-focused institutional invest |
|
| March 31, 2022 |
Exhibit 4.3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARAVIVE, INC. Warrant Shares: 1,665,025 Issue Date: March 31, 2022 Initial Exercise Date: March 31, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [ ] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter |
|
| March 31, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-248612 PROSPECTUS SUPPLEMENT (To the Prospectus dated November 20, 2020) 3,185,216 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,665,025 Shares of Common Stock Warrants to Purchase up to 4,850,241 Shares of Common Stock Up to 1,665,025 Shares of Common Stock underlying such Pre-Funded Warrants Up to 4,850,241 |
|
| March 31, 2022 |
Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates Exhibit 99.1 Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates ? Reported positive data from Phase 1b trials of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma in 1Q?22; on track to report updated data in 2Q?22 ? Dosed first patient in Phase 2 trial of batiraxcept in ccRCC in January 2022; on track to report preliminary |
|
| March 31, 2022 |
Exhibit 4.2 FORM OF COMMON STOCK PURCHASE WARRANT ARAVIVE, INC. Warrant Shares: 860,216 Issue Date: March 31, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [ ] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval (a |
|
| March 31, 2022 |
Exhibit 21.1 SUBSIDIARIES Aravive Biologics, Inc. (Delaware) |
|
| March 31, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 31, 2022 |
Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT ARAVIVE, INC. Warrant Shares: 3,990,025 Issue Date: March 31, 2022 Initial Exercise Date: March 31, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [ ] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| March 31, 2022 |
Exhibit 10.2 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 29, 2022, between Aravive, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions s |
|
| March 25, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 22, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 22, 2022 |
Exhibit 10.1 Aravive, Inc. River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, TX 77098 February 20, 2022 Leonard Scott Dove, Ph.D. 1060 Covered Bridge Dr. Driftwood, Texas 78619 Via Email Delivery: [email protected] Dear Dr. Dove, Aravive, Inc. (the "Company") is pleased to offer you employment on the following terms: 1) Position a) Your initial title will be Chief Operating Officer. Th |
|
| March 22, 2022 |
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer Exhibit 99.1 Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer HOUSTON, March 22, 2022 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of industry veteran, Scott Dove, Ph.D., as Chief Operating Officer. ?We are honored Dr. Dove is bringing his strong in |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 Aravive, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36361 26-4106690 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 3, 2022 |
Exhibit 99.1 Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma ? 46% Best Overall Response Rate in the ITT Population ? 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population ? 6-month Progression-Free Survival Rate in the ITT Population of 79% ? 6-month Progression-Free Survival Rate of 91% in th |
|
| March 3, 2022 |
Corporate Presentation of Aravive, Inc. dated March 2022 Exhibit 99.2 |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| February 11, 2022 |
ARAV / Aravive Inc / New Leaf Biopharma Opportunities Ii, L.p. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 3) Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03890D108 (CUSIP Number) December 31, 2021 (Date of Event Which Requ |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| January 31, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 Aravive, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36361 26-4106690 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 31, 2022 |
EX-99.1 2 ex329267.htm EXHIBIT 99.1 Exhibit 99.1 Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma Preliminary top line data anticipated throughout 2022 Houston, TX, January 31, 2022 – Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the Compa |
|
| January 19, 2022 |
4,545,455 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262020 PROSPECTUS 4,545,455 Shares of Common Stock This prospectus relates to the resale from time to time, by the selling stockholder identified in this prospectus under the caption ?Selling Stockholder,? of up to 4,545,455 shares of our common stock (the ?Warrant Shares?), par value $0.0001 per share (the ?Common Stock?), it may purchase upon |
|
| January 13, 2022 |
January 13, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Michael Davis Re: Aravive, Inc. Registration Statement on Form S-3 File No. 333-262020 Request For Acceleration of Effectiveness Ladies and Gentlemen: Aravive, Inc. (the ?Company?) hereby requests that the effective date of th |
|
| January 6, 2022 |
ARAV / Aravive Inc / ESHELMAN FREDRIC N - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 03890D108 (CUSIP Number) Fredric N. Eshelman Eshelman Ventures, LLC 319 North Third Street, Suite 301 Wilmington, North Carolina 28401 910-558-6885 with a copy |
|
| January 5, 2022 |
As filed with the Securities and Exchange Commission on January 5, 2022 Table of Contents As filed with the Securities and Exchange Commission on January 5, 2022 Registration Statement No. |
|
| January 4, 2022 |
EX-99.1 4 ex321157.htm EXHIBIT 99.1 Exhibit 99.1 Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors Houston, TX, January 3, 2022 – Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’ |
|
| January 4, 2022 |
Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARAVIVE, INC. Warrant Shares: 4,545,455 Initial Issuance Date: January 5, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Eshelman Ventures, LLC, a North Carolina limited liability company, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on ex |
|
| January 4, 2022 |
Corporate Presentation dated January 2022. Exhibit 99.2 |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 4, 2022 |
Exhibit 10.1 EXECUTION VERSION INVESTMENT AGREEMENT THIS INVESTMENT AGREEMENT (this ?Agreement?) is made and entered into on January 3, 2022, by and among Eshelman Ventures, LLC, a North Carolina limited liability company (the ?Investor?), Aravive, Inc., a Delaware corporation (the ?Company?), and, solely for purposes of Article IV and Article V, Fredric N. Eshelman, Pharm.D. (?Eshelman?). WITNESS |
|
| November 12, 2021 |
Corporate Presentation dated November 2021 Exhibit 99.3 |
|
| November 12, 2021 |
Exhibit 99.1 Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma 7 of 16 (44%) patients achieved best overall response of partial response Confirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up 14 of 16 (88%) patients demonstrated tumor decrease |
|
| November 12, 2021 |
Exhibit 99.2 |
|
| November 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Aravive, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36361 26-4106690 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora |
|
| November 9, 2021 |
Exhibit 99.1 Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting 3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline Batirxcept has been generally we |
|
| November 9, 2021 |
Table 1: Preliminary Clinical Activity in NCT04300140 Exhibit 99.2 A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment (NCT04300140) Background In clear cell renal cell carcinoma (ccRCC) the constitutive expression of hypoxia induced factor 1-? leads to increased expression of AXL. AXL overexpression has |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3636 |
|
| October 28, 2021 |
Investor Presentation, dated October 2021 Exhibit 99.2 |
|
| October 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 28, 2021 |
Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates Exhibit 99.1 Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates ? Dosed first patient in batiraxcept (formerly AVB-500) Phase 1b clinical trial in pancreatic adenocarcinoma ? Orphan drug designation granted by European Commission to batiraxcept in platinum resistant ovarian cancer ? New preliminary data from batiraxcept Phase 1b clinical trial in clear cell renal c |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Aravive, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36361 26-4106690 (State or Other (Commission (IRS Jurisdiction of File Employer Incorp |
|
| August 9, 2021 |
Investor Presentation of Aravive, Inc. dated August 2021 Exhibit 99.2 |
|
| August 9, 2021 |
Exhibit 99.1 Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel Continues Expansion of AVB-500 in Multiple Oncology Indications and Combinations Houston, TX, August 9, 2021 ? Aravive Inc. (Nasdaq: ARAV), a clinical-stage on |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36361 Ara |
|
| August 5, 2021 |
Exhibit 99.1 Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates ? Positive initial results from AVB-500 Phase 1b portion of Phase 1b/2 clinical trial in clear cell renal cell carcinoma; expect to initiate Phase 2 trial in second half of 2021 ? On track to initiate the AVB-500 Phase 1b/2 clinical trial in pancreatic adenocarcinoma in second half of 2021 ? Achieved |
|
| August 5, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 Aravive, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36361 26-4106690 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 15, 2021 |
Exhibit 99.1 Aravive Achieves Second Development Milestone from 3D Medicines Milestone is Based on Approval of 3D Medicines' IND in China to Participate in Aravive?s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer Houston, TX, July 15, 2021 ? Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening dis |
|
| June 24, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 Aravive, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36361 26-4106690 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 24, 2021 |
Exhibit 99.1 Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15mg/kg of AVB-500 Houston, TX, June 24, 2021 ? Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat l |
|
| June 14, 2021 |
Sublease Agreement by and between Aravive, Inc. and Grail, Inc. Exhibit 10.1 SUBLEASE THIS SUBLEASE (?Sublease?) is entered into as of June 8, 2021 (the ?Effective Date?), by and between ARAVIVE, INC., a Delaware corporation (?Sublandlord?) and GRAIL, INC., a Delaware corporation (?Subtenant?), with reference to the following facts: A. Pursuant to that certain Lease Agreement dated March 17, 2017, as amended by that certain Amendment to Lease dated December 14 |
|
| June 14, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 18, 2021 |
Exhibit 99.1 Aravive Announces Three New Appointments to its Board of Directors Further Strengthens Senior Executive Leadership Team HOUSTON, May 18, 2021 ? Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the appointments of John A. Hohneker, M.D., Sigurd C. Kirk, and Peter T.C. Ho, M.D., Ph.D. t |
|
| May 6, 2021 |
EX-99.2 3 arav-ex992126.htm EX-99.2 Corporate Presentation May 2021 Halting Disease Progression in its Tracks ARAV (NASDAQ) © 2021 Aravive, Inc. Exhibit 99.2 Forward-Looking Statements Forward Looking Statements © 2021 Aravive, Inc. 2 This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of op |
|
| May 6, 2021 |
Exhibit 99.1 Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer ? Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer ? First patient dosed in registrational Phase 3 trial of AVB-500 in platinu |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36361 Aravive, Inc. (Exact |
|
| April 27, 2021 |
Corporate Presentation April 2021 Halting Disease Progression in its Tracks ARAV (NASDAQ) ? 2021 Aravive, Inc. |
|
| April 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 27, 2021 |
Exhibit 99.1 Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer U.S. FDA Granted Fast Track Designation in 2018 Trial Expected to Enroll 300-400 Patients at Approximately 165 Sites in the U.S. and Europe in Simplified Adaptive Trial Desig |
|
| April 15, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03890D108 (CUSIP Number) Raymond Tabibiazar, M.D. c/o 526 Ventures 245 First Street, 18th floor Cambridge, Massachusetts 02142 April 12, 2021 |
|
| March 23, 2021 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03890D108 (CUSIP Number) Amato Giaccia c/o Aravive, Inc. River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 With a copy to: L |
|
| March 17, 2021 |
As filed with the Securities and Exchange Commission on March 17, 2021 Registration No. |
|
| March 16, 2021 |
Description of Capital Securities. EX-4.2 2 arav-ex4211.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Aravive, Inc. (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which is our common stock, par value $0.0001 per share (the “common stock”). G |
|
| March 16, 2021 |
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates Exhibit 99.1 Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates • Initiated a registrational trial of AVB-500 in Platinum Resistant Ovarian Cancer in 1Q 2021 • First patient dosed in Phase 1b/2 trial of AVB-500 in Clear Cell Renal Cell Carcinoma in 1Q 2021; On-track to report topline data in 2H 2021 • Strengthened balance sheet with $21.0 million reg |
|
| March 16, 2021 |
Exhibit 10.48 River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 September 8, 2020 Dear Reshma Rangwala: Aravive, Inc. (the ?Company?) is pleased to continue your employment as Chief Medical Officer of the Company and its subsidiaries on the following terms: 1.Position. (a)You will be employed as Chief Medical Officer (?CMO?) of the Company and you will report to the Company?s Chie |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36361 Aravive, Inc. ( |
|
| March 16, 2021 |
Exhibit 21.1 SUBSIDIARIES Aravive Biologics, Inc. (Delaware) |
|
| March 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 8, 2021 |
Exhibit 99.1 Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma Lead Compound AVB-500 Now Being Evaluated in Broad Range of Cancers Houston, TX, March 8, 2021 ? Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company has dosed its first patien |
|
| March 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 2, 2021 |
Corporate Presentation March 2021 Halting Disease Progression in its Tracks ARAV (NASDAQ) Exhibit 99. |
|
| March 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 19, 2021 |
EX-99.1 2 tm217204d1ex-1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation t |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 03890D108 (CUSIP Number) Fredric N. Eshelman 319 North Third Street, Suite 301 Wilmington, North Carolina 28401 with a copy to: Gregory P. Patti Jr., Esq. Cadwa |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aravive, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03890D108 (CUSIP Number) Qianye Karen Liu c/o BC Axis Limited, Suite 701, Tower C, Tsinghua Science Park, No 1. Zhongguancun East Road; Hainan Distric |
|
| February 16, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-248612 PROSPECTUS SUPPLEMENT (To the Prospectus dated November 20, 2020) 2,875,000 Shares Common Stock We are offering 2,875,000 shares of our common stock to Eshelman Ventures, LLC, a North Carolina limited liability company, for aggregate gross proceeds of approximately $20,958,750 pursuant to this prospectus supplement and the accompanying b |
|
| February 16, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?), dated as of February 12, 2021, is made by and between ARAVIVE, Inc., a Delaware corporation (the ?Company?), and Eshelman Ventures, LLC, a North Carolina limited liability company (the ?Purchaser?). The capitalized terms used herein and not otherwise defined have the meanings given them in Article 6. |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Aravive, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03890D108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 16, 2021 |
EX-99.1 2 d105908dex991.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the common stock, $0.0001 par value per share, of Aravive, Inc., dated as of February 12, 2021, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of |
|
| February 16, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 27, 2021 |
Exhibit 10.1 River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 Gail McIntyre (via email: XXX) January 25, 2021 Dear Gail: Aravive, Inc. (the “Company”) is pleased to enter into this amendment (“Amendment”) to your Offer Letter, dated March 26, 2020, as amended on April 8, 2021 (the “Offer Letter”), and hereby agrees to amend the Offer Letter as follows: 1. The first sentence of Se |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 Aravive, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36361 26-4106690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 4, 2021 |
Consulting Agreement, dated December 31, 2020, between the Company and Ray Tabibiazar Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of December 31, 2020 (“Effective Date”) by and between Aravive, Inc., a Delaware corporation (collectively with its subsidiaries, the “Company”), and Ray Tabibiazar (“Consultant”). Each of Company and Consultant are sometimes hereafter referred to as a “Party” or collectively as the “Parties. |
|
| January 4, 2021 |
Aravive Announces Board Member Transition to Advisory Role Exhibit 99.1 Aravive Announces Board Member Transition to Advisory Role Houston, TX, December 31, 2020 – Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be stepping down from the Aravive Board of Directors but will remain an advisor to the company, effective December 31, 2020. This transition will |
|
| November 20, 2020 |
As filed with the Securities and Exchange Commission on November 20, 2020 Registration Statement No. |
|
| November 19, 2020 |
© 2020 Aravive, Inc. Corporate Presentation November 2020 Halting Disease Progression in its Tracks ARAV (NASDAQ) Exhibit 99.2 © 2020 Aravive, Inc. Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- loo |
